Abstract
INTRODUCTION
Fatty acids (FAs) are the building blocks of complex lipids and signaling compounds; the role of the lipidome fatty acid profile (LFA) in AD progression remains unclear.
METHODS
The LFA of plasma and cerebrospinal fluid (CSF) samples from 289 participants (103 AD patients, 92 MCI patients, and 94 controls) was determined by GC-FID. The MCI subjects were followed up for 58 ± 12.5 months.
RESULTS
In controls, CSF has a more neuroprotective LFA than plasma. In CSF, a higher content of docosahexaenoic acid was associated with a reduced risk of MCI-to-AD progression. In plasma, higher oleic acid content was associated with lower risk of AD, MCI, and MCI-to-AD progression, whereas higher levels of vaccenic acid and docosahexaenoic acid were associated with greater risk of AD and MCI, and higher rate of MCI-to-AD progression, respectively.
DISCUSSION
The circulating LFA is involved in the pathogenesis and progression of AD.
Highlights
The lipidome fatty acid profile in CSF and plasma was markedly different.
Higher levels of vaccenic acid and lower levels of oleic acid in plasma were associated with greater risk of Alzheimer’s disease.
In plasma, higher levels of oleic acid were associated with a reduced risk of MCI-to-AD progression.
Higher levels of docosahexaenoic acid in CSF were associated with a lower risk of MCI-to-AD progression.
Higher levels of docosahexaenoic acid in plasma were associated with a greater rate of MCI-to-AD progression.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Farida Dakterzada,
Mariona Jové,
José Luís Cantero,
Natàlia Mota‐Martorell,
Reinald Pamplona,
Gerard Piñoll‐Ripoll | March 27, 2024